NovaSight Overview
NovaSight is medical device company with a mission to prevent vision impairments among pediatric patients using eye tracking based technology in novel diagnostic, therapeutic and preventive solutions, especially designed for the unique needs of children. NovaSight focuses on three major verticals: vision treatment, vision diagnostics and prevention and monitoring of visual health conditions. Available in the US and Italy, the CureSight™ is an FDA cleared and CE marked amblyopia treatment system, designed to replace the traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from the comfort of home. By tracking the gaze position of the dominant eye in real-time, the CureSight system blurs its center of vision, while keeping the rest of the image sharp - and providing the amblyopic eye with a normal, high contrast, image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together. In addition, the CureSight system is connected to a dedicated cloud platform which allows the physician to monitor treatment progress and compliance remotely. The EyeSwiftPRO tests are grouped into automated ‘protocols’ such as amblyopia monitoring, binocular vision, etc. with each protocol running the unitary tests that are of clinical relevance to the protocol. At the end of each protocol, a clear report which is easily understood by the operator and the patient is created. NovaSight is also in the process of developing TrackSight™, a software as a service (SaaS) solution for myopia prevention and visual health monitoring. TrackSight is designed for use by children on laptops and tablets for both educational and leisure purposes as well as adults at the workplace for objective eye fatigue and dry eye monitoring.
Cumulative Funding Raised Over Time ($)
$8.0MApr 2022
$8.8MJan 2015
$24.8MJul 2020
$24.8MJul 2025
$29.8MMar 2024
Latest News
growth-positive
Binocular amblyopia home treatment: The next step after patching
The article discusses a study comparing the efficacy of a binocular, eye-tracking-based home treatment for amblyopia, CureSight, developed by NovaSight, against traditional patching. The study, published in the American Journal of Ophthalmology, involved 149 children aged 4 to 9 years and demonstrated that CureSight is at least as effective as patching in improving visual acuity. CureSight encourages binocular vision, reducing interocular suppression, and showed higher adherence rates compared to patching. The study found that both treatments improved visual acuity, with CureSights improvement margin within the acceptable range of noninferiority to patching. The findings suggest that CureSight is a safe and engaging alternative to patching, with significant benefits for patients.
growth-positive
CureSight demonstrates greater visual acuity gains vs. patching in patients with amblyopia
NovaSights CureSight digital eye-tracking system has demonstrated superiority over traditional patching methods in treating amblyopia, according to a study published in the American Journal of Ophthalmology. The study involved 149 children aged 4 to under 9 years, comparing the CureSight system with patching over a 16-week period. Results showed a significant improvement in visual acuity and treatment adherence in the CureSight group. The mean improvement in visual acuity was 0.28 logMAR for CureSight users compared to 0.23 logMAR for those using patches. Adherence to the CureSight regimen was also higher at 94% compared to 83.9% for patching. This breakthrough highlights NovaSights innovative approach to amblyopia treatment.
growth-positive
בהובלת קרן ההון סיכון הישראלית-סינית אינפיניטי: נובה-סייט גייסה 5 מיליון דולר | כלכליסט
Nova-Sight, a company developing medical equipment for eyes, has raised $5 million in a funding round led by Infinity, an Israeli-Chinese venture capital fund. The total funding round is expected to reach $10 million. The funds will be used to expand the companys global marketing and R&D activities. Nova-Sights device, CureSight, is designed to treat lazy eye in children and has shown significant improvement in vision clarity in clinical trials. The company, based in Airport City, employs 21 people.
InvestmentExpand
growth-positive
NovaSight reports long-term vision gains in CureSight study
NovaSight, a medical equipment manufacturer specializing in vision care solutions, has released 1-year follow-up outcomes for its CureSight treatment for amblyopia. The treatment, which uses AI and eye-tracking technologies, is designed to replace traditional eye patching methods. The study found that patients using CureSight showed significant improvement in visual acuity and stereoacuity compared to those using eye patches. The CureSight system was also found to significantly improve vision in amblyopic pediatric patients at least 1-year post-treatment.
Customers
growth-positive
NovaSight publishes CureSight's pivotal study of 1-year follow-up outcomes
NovaSights CureSight, a digital at-home treatment for amblyopia (lazy eye), has demonstrated long-term vision gains in a study published in the American Journal of Ophthalmology. The study found that children showed significant improvement in visual acuity and stereoacuity following short-term binocular treatment with CureSight, and these gains were maintained for at least one year. Following FDA clearance in October 2022, NovaSight launched the CureSight Referral Program in the US in early 2023, which has been adopted by over 250 eye care providers and generated more than 650 patient referrals. NovaSight is planning a full commercial rollout in the US, Europe, and China in 2024.
CustomersInvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $30.97M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 6 |
| Investors | 9 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | nova-sight.com |
Locations
Lod, Israel
Virginia, USA
Photos & Videos
11 item(s)
NovaSight Business
Business models
B2B2C, B2B, B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsDigital HealthcareDigital Medical DiagnosticsTarget Customer
ConsumersDemographics & FamilyChildrenHealthcare & Life SciencesHealthcareProvidersCore Technology
Semiconductors & ElectronicsWearablesPlatforms & InterfacesSoftwareData StorageCloudArtificial IntelligenceDeep LearningComputer VisionTags (35)
patient-carecloudsensorssoftware-applicationsopticsdeep-learningartificial-intelligencewearablehealthcarechildrendiagnosticshospitalsophthalmologydoctorseye-diseasesmedical-deviceshealthcare-providerscomputer-visiondigital-healthcareearly-detectionscreeningdata-analyticsnon-invasivebig-datareal-timeparentstelemedicineeye-trackingoptronicsdigital-therapeuticstreatmentshome-careconsumersmedical-technologiestrainingGeographic Markets
GlobalNovaSight Financials
$30.97M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
A
Funding stage
6
Total rounds
9
Investors
Cumulative Funding Raised Over Time ($)
$8.0MApr 2022
$8.8MJan 2015
$24.8MJul 2020
$24.8MJul 2025
$29.8MMar 2024
Private Equity Funding
A Round
Jul 2025
Undisclosed
Sanara Capital
B Round
Mar 2024
$5M
Infinity China (Lead)
A Round
Apr 2022
$8M
Rimonci Capital, Yongzhu, Zhuhai Ruikun, Santen Ventures
A Round
Jul 2020
$16M
Rimonci Capital (Lead)
,
Santen Ventures, Club 100 Plus, Essilor
Seed
Jan 2015
$840K
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
Jan 2019
$1.13M
NovaSight Lifecycle
Cumulative Funding Raised Over Time
$8.0MApr 2022
$8.8MJan 2015
$24.8MJul 2020
$24.8MJul 2025
$29.8MMar 2024
All Events
A Round
Jul 2025
Undisclosed
Sanara Capital
B Round
Mar 2024
$5M
Infinity China (Lead)
A Round
Apr 2022
$8M
Rimonci Capital, Yongzhu, Zhuhai Ruikun, Santen Ventures
A Round
Jul 2020
$16M
Rimonci Capital (Lead)
,
Santen Ventures, Club 100 Plus, Essilor
Seed
Jan 2015
$840K
Undisclosed Investor(s)
GrantEvent
Jan 2019
$1.13M
NovaSight News
24 articles
growth-positive
Binocular amblyopia home treatment: The next step after patching
The article discusses a study comparing the efficacy of a binocular, eye-tracking-based home treatment for amblyopia, CureSight, developed by NovaSight, against traditional patching. The study, published in the American Journal of Ophthalmology, involved 149 children aged 4 to 9 years and demonstrated that CureSight is at least as effective as patching in improving visual acuity. CureSight encourages binocular vision, reducing interocular suppression, and showed higher adherence rates compared to patching. The study found that both treatments improved visual acuity, with CureSights improvement margin within the acceptable range of noninferiority to patching. The findings suggest that CureSight is a safe and engaging alternative to patching, with significant benefits for patients.
growth-positive
CureSight demonstrates greater visual acuity gains vs. patching in patients with amblyopia
NovaSights CureSight digital eye-tracking system has demonstrated superiority over traditional patching methods in treating amblyopia, according to a study published in the American Journal of Ophthalmology. The study involved 149 children aged 4 to under 9 years, comparing the CureSight system with patching over a 16-week period. Results showed a significant improvement in visual acuity and treatment adherence in the CureSight group. The mean improvement in visual acuity was 0.28 logMAR for CureSight users compared to 0.23 logMAR for those using patches. Adherence to the CureSight regimen was also higher at 94% compared to 83.9% for patching. This breakthrough highlights NovaSights innovative approach to amblyopia treatment.
growth-positive
בהובלת קרן ההון סיכון הישראלית-סינית אינפיניטי: נובה-סייט גייסה 5 מיליון דולר | כלכליסט
Nova-Sight, a company developing medical equipment for eyes, has raised $5 million in a funding round led by Infinity, an Israeli-Chinese venture capital fund. The total funding round is expected to reach $10 million. The funds will be used to expand the companys global marketing and R&D activities. Nova-Sights device, CureSight, is designed to treat lazy eye in children and has shown significant improvement in vision clarity in clinical trials. The company, based in Airport City, employs 21 people.
InvestmentExpand
growth-positive
NovaSight reports long-term vision gains in CureSight study
NovaSight, a medical equipment manufacturer specializing in vision care solutions, has released 1-year follow-up outcomes for its CureSight treatment for amblyopia. The treatment, which uses AI and eye-tracking technologies, is designed to replace traditional eye patching methods. The study found that patients using CureSight showed significant improvement in visual acuity and stereoacuity compared to those using eye patches. The CureSight system was also found to significantly improve vision in amblyopic pediatric patients at least 1-year post-treatment.
Customers
growth-positive
NovaSight publishes CureSight's pivotal study of 1-year follow-up outcomes
NovaSights CureSight, a digital at-home treatment for amblyopia (lazy eye), has demonstrated long-term vision gains in a study published in the American Journal of Ophthalmology. The study found that children showed significant improvement in visual acuity and stereoacuity following short-term binocular treatment with CureSight, and these gains were maintained for at least one year. Following FDA clearance in October 2022, NovaSight launched the CureSight Referral Program in the US in early 2023, which has been adopted by over 250 eye care providers and generated more than 650 patient referrals. NovaSight is planning a full commercial rollout in the US, Europe, and China in 2024.
CustomersInvestmentExpand
growth-positive
Israeli 3D Glasses To Combat Lazy Eye
NovaSight, an Israeli startup, has developed a new treatment for lazy eye (amblyopia) that allows children to treat their condition at home. The treatment, called CureSight, uses a specially developed tablet device and 3D-vision glasses to track the gaze of both eyes in real time using an AI sensor. The child watches any streamed video content of their choice through red-blue treatment glasses, which stimulate the brain to use the information of the lazy eye to process the fine details. The treatment has been found to be more effective than traditional patch treatment, with 79% of patients experiencing better vision correction after four months of use.
CustomersPartners
growth-positive
NovaSight CureSight (TM) Wins 2023 MedTech Breakthrough Award
NovaSights CureSight binocular digital treatment system for amblyopia (lazy eye) has been named Best New Technology Solution for Ophthalmology in the 7th annual MedTech Breakthrough Awards program. CureSight is an FDA-cleared and CE marked eye-tracking based amblyopia treatment system, designed to replace traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from home. The CureSight system blurs the center of vision of the dominant eye, while providing the amblyopic eye with a normal, high contrast image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together.
Customers
Growth-Positive
Insights on amblyopia therapies - EyeWorld
Tech-based options for the treatment of amblyopia, such as CureSight by NovaSight and Luminopia, have received FDA approval and are now available on the market. These therapies allow for binocular treatment rather than monocular and have several studies published in peer review supporting their therapeutic benefits. However, patient compliance can pose a problem due to factors such as limited viewing options, the need for hardware and internet, and cost. Despite these challenges, these innovative therapies are applauded for improving the patient experience and compliance.
CustomersPartners
growth-positive
NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketing - Eyewire+
NovaSight has announced the US release of its CureSight digital therapy for amblyopia. The device received FDA clearance based on a study that found it to be as effective as eye patching, the current standard of care. The therapy is carried out at home while the child watches streamed content on a user-friendly device, with treatment reports shared via a web portal. NovaSight also announced the appointment of Drew Hopper as Vice President of Sales and Marketing North America. The company aims to reach coverage from the top five US insurance payers in 2023.
CustomersManagement Changes
growth-positive
NovaSight Announces FDA 510(K) Clearance of CureSight Digital Therapy for Amblyopia
NovaSight, a pediatric-focused eyecare company, has received clearance from the U.S. Food and Drug Administration (FDA) for CureSight, a digital therapy device for amblyopia. The device uses eye-tracking technology to improve visual and stereo acuity by training the visual system to use both eyes simultaneously. The FDA clearance was based on a study conducted in six medical centers in Israel. NovaSight recently raised $7 million in a SAFE (Simple Agreement for Future Equity) round, bringing the total amount raised by the company to $26 million. The funds will be used for the targeted commercialization of CureSight in the U.S.
Investment
growth-positive
NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial
NovaSight, a pediatric-focused eyecare company, has announced positive data from its trial of CureSight, a digital treatment device for amblyopia, also known as lazy eye. The study demonstrated that the device was non-inferior to traditional eye patching treatment. The company also reported high patient satisfaction and adherence to the CureSight treatment. NovaSight has initiated a Series B financing round in addition to the $20 million it has already raised. The company is also preparing to submit its application for FDA clearance of the device.
CustomersInvestment
growth-positive
NovaSight Is Assigned Three Unique CPT Codes by AMA for CureSight Amblyopia Treatment
NovaSight, a pediatric-focused eyecare company, has reached key milestones in the development of its CureSight digital treatment device for amblyopia, or lazy eye. The American Medical Association (AMA) has assigned three unique billing codes to the companys technology, marking the first time the AMA has awarded codes to an eye-tracking amblyopia treatment. These codes will allow physicians and patients to potentially be reimbursed for the use of CureSight. NovaSight is also sponsoring a clinical trial that will generate data about CureSight for inclusion in an early 2022 FDA clearance submission. The company is seeking additional partners for a series B funding effort anticipated to total $15 million.
CustomersPartnersInvestmentExpand
growth-positive
NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eye - Eyewire+
NovaSight has announced significant progress towards the launch of its CureSight digital treatment device for amblyopia, or lazy eye. The American Medical Association (AMA) has assigned three unique billing codes to the companys technology, marking the first time the AMA has awarded codes to an eye-tracking amblyopia treatment. This will allow physicians and patients to potentially be reimbursed for using CureSight. NovaSight is also sponsoring a clinical trial to generate data about CureSight for inclusion in a 2022 FDA clearance submission. The company is seeking additional partners for a series B funding effort anticipated to total $15 million.
CustomersPartnersInvestmentExpand
growth-positive
VIDEO: CureSight platform offers amblyopia therapy
Ran Yam, CEO of NovaSight, discusses two upcoming product lines, CureSight and ActiveSight glasses. The company is planning the next steps for these products.
Customers
growth-positive
NovaSight eyes FDA clearance with upcoming clinical trial
NovaSight, an Israeli digital eye treatment startup, has announced a clinical trial for its CureSight system, which aims to treat amblyopia, or lazy eye, without the need for patching. The device uses artificial intelligence eye-tracking technology to blur what the dominant eye sees, thereby strengthening the weaker eye. The device can be used at home and shares treatment reports with caregivers and parents through a mobile app. The new study is seeking 90 children with amblyopia between 4 and 9 years old and will take place in six different medical centers across Israel.
InvestmentExpand
growth-positive
Israeli AI eye tracking co NovaSight raises $8m
Israeli vision care company NovaSight has raised $8 million in a Series A financing round led by Rimonci Capital, bringing the total amount raised by the company to $16 million. The funds will be used to advance research for the companys lazy eye treatment device and eye care products such as innovative eye tracking based active glasses for myopia control. The company is also focusing on developing telehealth solutions for remote diagnostics and home treatment.
Investment
growth-positive
NovaSight launches two telehealth technologies
NovaSight has launched two products aimed at improving telehealth platforms through remote diagnostics and digital treatments. The EyeSwift is a vision assessment tool that monitors patient’s eye movements and provides evaluation of vision impairments. The CureSight specializes in lazy eye treatment, replacing traditional eye patching therapy with 3D image processing algorithms and patient progress monitoring. The systems treatment protocol is automatically adjusted through artificial intelligence.
CustomersExpand
growth-positive
NovaSight Answers Global Need For Ophthalmology Telehealth Solutions During Coronavirus Pandemic
Israeli startup NovaSight has launched two eye-tracking based telehealth solutions for vision care, focusing on childrens vision. The CureSight system and the EyeSwift vision assessment system aim to provide improved remote diagnostics and digital treatments amidst the COVID-19 pandemic. The EyeSwift system, which provides 11 different vision exams, is currently marketed by NovaSights strategic partner, Essilor. NovaSights CureSight is an eye-tracking based system for lazy eye treatment, intended to replace traditional eye patching therapy. The company plans to conduct a large multicenter randomized trial during 2020.
CustomersPartners
This Startup Cures Lazy Eye With Netflix and Disney
growth-positive
Kids with lazy eye can be treated just by letting them watch TV on this special screen
NovaSight has developed a new treatment for amblyopia, commonly known as lazy eye, that doesnt require the traditional method of wearing an eye patch. The companys CureSight technology uses a special display that selectively blurs content, forcing the affected eye to work harder and align itself properly. The treatment can be done at home and requires only an hour a day. NovaSight has already conducted limited clinical trials that showed significant improvement over a 12-week period. The company is planning further trials to determine if the treatment can completely cure the condition.
Customers
growth-positive
NovaSight Leverages Netflix and Disney to Cure Vision Disorders
NovaSight, a provider of digital healthcare platforms, is set to present its AI-driven eye tracking solutions for vision care at CES 2020. The companys CureSight solution aims to replace traditional eye patching for amblyopia treatment with AI and eye tracking technologies. The system uses eye tracking technology to blur the gaze position of the dominant eye, forcing the brain to use the amblyopic eye. NovaSight has also signed a global OEM distribution agreement with Essilor for its EyeSwift system, an automated, objective, and easy-to-use eye tracking based vision assessment system.
CustomersPartners
Growth-Positive
NovaSight Archives - ISRAEL21c
The article introduces Keep It Magniv, a community focused on sustainability, environmentalism, and combating climate change. The platform aims to make a positive global impact and is inviting people to join and contribute to its cause. No specific details about partnerships, investments, or customers are mentioned.
Customers
growth-positive
Diagnosing vision problems from eye movement
Israeli company NovaSight has developed a system that diagnoses and treats vision problems in children by monitoring eye movements. The system is particularly effective in diagnosing and treating lazy eye and convergence insufficiency. The company was founded by Dan Oz, who previously co-founded Sightline, a colonoscopy company that was sold to Stryker for $50 million. NovaSights product has been approved for marketing in Europe and is currently being tested on children. The company is also in talks with an international company to integrate its products into devices sold to ophthalmologists clinics.
CustomersPartnersExpand
growth-positive
10 breakthrough health techs emerging from Israel
The annual MIXiii-Biomed conference in Tel Aviv, Israel showcased 45 startups developing healthcare products in various fields. The event, sponsored by the Israel Innovation Authority (IIA), featured a competition for Biomed Startup of the Year. The winners were CorNeat Vision, which has developed an artificial cornea, and PixCell Medical, which is developing a bedside blood-count device. Other notable startups included SpacePharma, which is making experiments in space more accessible and affordable, and NovaSight, which has developed a technology based on eye-tracking to help children with vision disorders.
CustomersPartners
NovaSight Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 14 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 20 classification IDs that could be used for matching.
NovaSight Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514734516 |
| Crunchbase | novasight-8b62 |
| Phone | +97236422868 |
| Creator | Vered Waxman |
| Creator email | vered.waxman@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-08-26T00:00:00.000Z |
| Created | 2017-11-21T00:00:00.000Z |
| Claimed | Yes |